Management of Achalasia
For primary achalasia in adults, pneumatic balloon dilation (starting with 30mm, advancing to 35mm) or laparoscopic Heller myotomy with fundoplication should be offered as first-line definitive therapy, with peroral endoscopic myotomy (POEM) considered as an equivalent option when local expertise is available, particularly for type III achalasia. 1, 2
Initial Treatment Selection Algorithm
The choice between therapeutic modalities depends on:
Pneumatic Dilation (PD): Start with 30mm balloon in first session, advance to 35mm at 2-28 days, consider 40mm if Eckardt score remains >3. Effective in 90% at 1 year, 86% at 2 years. 1
Laparoscopic Heller Myotomy (LHM): Provides superior long-term success at 5 years (OR 6.39) compared to pneumatic dilation. 3
POEM: Comparable efficacy to LHM at 5 years (OR 6.33), with particular advantage for type III achalasia. Requires 20-40 procedures for operator competence. 2, 3
Specific Technical Approach for Pneumatic Dilation
Begin with 30mm pneumatic balloon positioned at the esophagogastric junction, inflated for 1-3 minutes under endoscopic or fluoroscopic guidance. 1 Perform second session 2-28 days later with 35mm balloon. 1 If symptoms persist (Eckardt score >3), proceed to third session with cautious 40mm balloon use. 1
The graded approach reduces perforation risk while maintaining efficacy. Fluoroscopy is traditionally preferred but endoscopic control alone has proven safe when expertise exists. 1
Critical Post-Procedure Management
All patients require proton pump inhibitor therapy after any myotomy procedure due to 10-40% rate of symptomatic GERD or ulcerative esophagitis. 1 This is particularly crucial after POEM, where abnormal acid exposure occurs in 41-56% and esophagitis in 41-65% of patients. 4
Monitor patients for at least 2 hours post-procedure. Watch specifically for persistent chest pain, fever, breathlessness, or tachycardia—these mandate urgent CT with oral contrast to exclude perforation. 1 Transient chest pain is common and does not require imaging.
Management of Treatment Failure
For recurrent symptoms after initial myotomy, POEM demonstrates superior efficacy over repeat pneumatic dilation (62% vs 27% success rate). 4 However, one-third of patients may experience symptom recurrence during 4-6 years of follow-up after pneumatic dilation, with most successfully managed by repeat dilation achieving 97% and 93% remission at 5 and 10 years respectively. 1
Before repeat intervention, perform comprehensive re-evaluation with esophagogastroduodenoscopy, high-resolution manometry, and timed barium esophagram. 4
Key Comparative Outcomes
Recent network meta-analysis shows POEM and LHM have comparable 1-year efficacy (RR 1.09), both superior to pneumatic dilation. 5 However, POEM carries higher esophagitis risk (5.3% vs 3.7% for LHM) but lower serious adverse event rate (1.4% vs 6.7% for LHM). 5
Pneumatic dilation results in significantly higher residual lower esophageal sphincter pressure and greater abnormal esophageal acid exposure compared to surgical options. 3
Important Caveats
Botulinum toxin injection is significantly inferior to all other modalities at 1 year (OR 0.10) and should be reserved only for elderly patients or those at prohibitively high surgical risk. 6, 3 It requires repeated injections with progressively diminishing benefit.
Water-soluble contrast swallow after dilation may be considered to screen for perforation but is not essential—routine imaging has not revealed clinically unsuspected perforations. 1
Post-POEM patients require indefinite PPI therapy and consideration for surveillance endoscopy given the 5-fold increased esophageal cancer risk in achalasia patients. 2, 4 Follow-up endoscopy and/or pH monitoring should be performed 6-12 months post-procedure for objective evaluation of acid exposure.
The evidence strongly supports definitive mechanical disruption of the lower esophageal sphincter over pharmacologic approaches, with treatment selection guided by achalasia subtype (particularly type III favoring POEM), local expertise, patient age and comorbidities, and acceptance of post-procedure reflux management requirements.